For patients with GN, FGF23 (HR 1.051 (95% CI 1.019–1.084)) and FMD (HR 0.522 (95% CI 0.300–0.908)) and for patients with amyloidosis, FGF23 (HR 1.035 (95% CI 1.012–1.058)), FMD (HR 0.216 (95% CI 0.109–0.430)) and hsCRP (HR 0.961 (95% CI 0.915–1.009)) independently contributed to the risk of CVDEs (Table 3). Here, FGF23 is linked to ganglioneuroma.